Company: NIVFW
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001213900-25-033966
Chunk: 176

Company: NewGenIvf Group Ltd
Filing Date: 2025-04-22
Form: 20-F
Item: Item 19
Chunk 176
---
 2024, the Company is authorized to issue10,000,000ordinary shares. Each ordinary share is entitled toonevote. The
holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the Board
of Directors of the Company.

The equity of the Company
as of December 31, 2024 and 2023 represents1,138,519and507,469ordinary shares with par value of $ Nil. The number of shares as above
have taken into consideration the reverse stock split effected on February 11, 2025 at an exchange ratio of one (1) share for twenty (20)
shares. Pursuant to ASC 505 the reverse stock split has been applied retrospectively.

F-23

Additional paid-in capital

  Balance as at January 1,2023                                                                  1,464,959  
  Issuance of shares as compensation for services ( Note 1)                                     2,866,856  
  Balance as at December 31, 2023                                                               4,331,815  
  Issuance of shares through Equity Line of Credit ( Note 2)                                    1,936,236  
  Issuance of shares through conversion of convertible notes                                    2,650,000  
  Decrease in subscription receivable due to reduction of work by professionals (Note 1)      ( 2,766,856  
  Business Combination ( Note 3)                                                              ( 6,028,690  
  Balance as at December 31, 2024                                                                 122,505  

  - the number of shares below have been amended to apply the  
  reverse stock split in February 2025 retrospectively.        
 ───────────────────────────────────────────────────────────────

Note 1: On January 10, 2023, the Company issued 1,365 10 812,300 3,450 10 2,054,556

Note 2: On November 21, 2024, the Company
entered into a Common Shares Purchase Agreement (the “ White Lion Purchase Agreement”) with White Lion Capital, LLC (“ White
Lion”) and a related Registration Rights Agreement (the “ RRA”). Pursuant to the White Lion Purchase Agreement, the Company
has the right, but not the obligation, to require White Lion to purchase, within 36 months from the Agreement effective date up to One
Hundred Million Dollars ($100,000,000) in